Insmed Incorporated

Healthcare · Biotechnology · United States

Last price 112.58 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 24.70B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 ...